Press Release Apr 16 2026
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the receipt of an Establishment Inspection Report from the USFDA for its oncology injectable manufacturing facility in Ahmedabad. The report pertains to a Pre-Approval Inspection conducted at the site in late November of the previous year. This disclosure is made in accordance with regulatory requirements for transparency to investors and exchange members.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 08 2026
- Press Release Mar 21 2026
- Press Release Mar 19 2026
- AeroDel signs exclusive licensing arrangement with Zydus for launching Aerolife Mini™, India's First Foldable, 'Always Attached' pMDI Enhancer
- Press Release Mar 18 2026
Later from Zydus Lifesciences
- Press Release Apr 25 2026
- Press Release May 06 2026
- Press Release May 19 2026
- Zydus Cancer Hospital, Ahmedabad marks 200+ Stereotactic Radiotherapy (SRT)/SRS for Brain Tumours
- Press Release May 28 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences